EPIK-O/ENGOT-OV61: A PHASE 3, RANDOMIZED STUDY OF ALPELISIB plus OLAPARIB IN PATIENTS WITH NO GERMLINE BRCA MUTATION DETECTED, PLATINUM-RESISTANT OR -REFRACTORY, HIGH-GRADE SEROUS OVARIAN CANCER
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER（2022）
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要